Balaban, E. P. et al. Locally advanced, unresectable pancreatic cancer: american society of clinical oncology clinical practice guideline. J. Clin. Oncol. 34, 2654–2668 (2016).
He, C. et al. Immunomodulatory effect after irreversible electroporation in patients with locally advanced pancreatic cancer. J. Oncol. 2019, 9346017 (2019).
Ruarus, A. H. et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology 294, 212–220 (2020).
Narayanan, J. S. S. et al. Irreversible electroporation combined with checkpoint blockade and TLR7 stimulation induces antitumor immunity in a murine pancreatic cancer model. Cancer Immunol. Res. 7, 1714–1726 (2019).
Zhao, J. et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat. Commun. 10, 899 (2019).
Clark, C. E. et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518–9527 (2007).
Feig, C. et al. The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266–4276 (2012).
Martinez-Bosch, N., Vinaixa, J. & Navarro, P. Immune evasion in pancreatic cancer: from mechanisms to therapy. Cancers 10, 6 (2018).
Martin, R. C.II., McFarland, K., Ellis, S. & Velanovich, V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann. Surg. Oncol. 20 (Suppl 3), S443–449 (2013).
Varshney, S. et al. Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety. JOP 7, 74–78 (2006).
Moir, J. et al. Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Eur. J. Surg. Oncol. 40, 1598–1604 (2014).
Martin, R. C. II et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann. Surg. 262, 486–494 (2015). discussion 492-484.
Rubinsky, B., Onik, G. & Mikus, P. Irreversible electroporation: a new ablation modality–clinical implications. Technol. Cancer Res. Treat. 6, 37–48 (2007).
Lin, M. et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. J. Cancer Res. Clin. Oncol. 143, 2607–2618 (2017).
Lin, M. et al. Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. Immunol. Lett. 186, 20–27 (2017).
Scheffer, H. J. et al. Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I/II PANFIRE study. Radiology 282, 585–597 (2017).
Bhutiani, N. et al. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. J. Surg. Oncol. 114, 181–186 (2016).
Bulvik, B. E. et al. Irreversible electroporation versus radiofrequency ablation: a comparison of local and systemic effects in a small-animal model. Radiology 280, 413–424 (2016).
Scheffer, H. J. et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology 8, 1652532 (2019).
Hu, Y. et al. Selenium nanoparticles as new strategy to potentiate gammadelta T cell anti-tumor cytotoxicity through upregulation of tubulin-alpha acetylation. Biomaterials 222, 119397 (2019).
Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).
Silva-Santos, B., Mensurado, S. & Coffelt, S. B. Gammadelta T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19, 392–404 (2019).
Zajdel, A., Kalucka, M., Chodurek, E. & Wilczok, A. DHA but not AA enhances cisplatin cytotoxicity in ovarian cancer cells. Nutr. Cancer 70, 1118–1125 (2018).
Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357 (2005).
Bouet-Toussaint, F. et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol. Immunother. 57, 531–539 (2008).
Dieli, F. et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450–7457 (2007).
Meraviglia, S. et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290–297 (2010).
Alnaggar, M. et al. Allogenic vgamma9vdelta2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J. Immunother. Cancer 7, 36 (2019).
Xiang, Z. & Tu, W. Dual face of vgamma9vdelta2-T cells in tumor immunology: anti- versus pro-tumoral activities. Front. Immunol. 8, 1041 (2017).
Lin, M. et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J. Clin. Investig. 130, 2560–2569 (2020).
Okazaki, T. et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212–1218 (2013).
Mansson, C. et al. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur. J. Surg. Oncol. 42, 1401–1406 (2016).
Narayanan, G. et al. Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J. Vasc. Interv. Radiol. 28, 342–348 (2017).
Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31–46 (2018).
Thind, K., Padrnos, L. J., Ramanathan, R. K. & Borad, M. J. Immunotherapy in pancreatic cancer treatment: a new frontier. Ther. Adv. Gastroenterol. 10, 168–194 (2017).
Yang, Y. et al. Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer. Cardiovasc. Interv. Radiol. 42, 48–59 (2019).
Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).
Willcox, B. E. & Willcox, C. R. Gammadelta TCR ligands: the quest to solve a 500-million-year-old mystery. Nat. Immunol. 20, 121–128 (2019).
Geller, M. A. & Miller, J. S. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 3, 1445–1459 (2011).
Field, W., Rostas, J. W. & Martin, R. C. G. Quality of life assessment for patients undergoing irreversible electroporation (IRE) for treatment of locally advanced pancreatic cancer (LAPC). Am. J. Surg. 218, 571–578 (2019).
Rossi, C. et al. Boosting gammadelta T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. Oncoimmunology 8, 1554175 (2019).
Benyamine, A. et al. BTN3A is a prognosis marker and a promising target for Vgamma9Vdelta2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Oncoimmunology 7, e1372080 (2017).
Chauvin, C. et al. NKG2D controls natural reactivity of vgamma9vdelta2 T lymphocytes against mesenchymal glioblastoma cells. Clin. Cancer Res. 25, 7218–7228 (2019).
Capietto, A. H., Martinet, L. & Fournie, J. J. Stimulated gammadelta T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J. Immunol. 187, 1031–1038 (2011).
Zeng, J. et al. The safety and efficacy of irreversible electroporation for large hepatocellular carcinoma. Technol. Cancer Res. Treat. 16, 120–124 (2017).
